Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04434469 · OUTCOME

Area Under the Curve (AUC) of RO7297089

A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma · Source last updated 2024-07-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
ug/mL*day
Interval / dispersion
Standard Deviation
Time frame
Cycle 1 Day 1

Analysis population: Only those participants who received full dose were included in the results summary

Groups in this outcome

Dose Escalation Cohort 1: RO7297089

Participants in Arm A received 60 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit

Dose Escalation Cohort 2: RO7297089

Participants in Arm A received 180 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit

Dose Escalation Cohort 3: RO7297089

Participants in Arm A received 360 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit

Dose Escalation Cohort 4: RO7297089

Participants in Arm A received 1080 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit

Dose Escalation Backfill Cohort 4: RO7297089

Participants in Arm B received the 1080 mg dose of RO7297089 as a split dose divided over two days (Days 1 and 2). The full target dose wasadministered at subsequent study drug administration visits.

Dose Escalation Cohort 5: RO7297089

Participants in Arm B received the 1850 mg dose of RO7297089 as a split dose divided over two days (Days 1 and 2). The full target dose was administered at subsequent study drug administration visits.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dose Escalation Cohort 1: RO72970893
Dose Escalation Cohort 2: RO72970894
Dose Escalation Cohort 3: RO72970893
Dose Escalation Cohort 4: RO72970891
Dose Escalation Backfill Cohort 4: RO72970894
Dose Escalation Cohort 5: RO72970893

Reported measurements

Source class 1
Values in ug/mL*day · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Dose Escalation Cohort 1: RO729708912.726.3Not reportedNot reportedNot reported
Dose Escalation Cohort 2: RO729708978.731.3Not reportedNot reportedNot reported
Dose Escalation Cohort 3: RO729708928073.6Not reportedNot reportedNot reported
Dose Escalation Cohort 4: RO72970891347NANot reportedNot reportedOnly 1 participant analyzed
Dose Escalation Backfill Cohort 4: RO7297089104628.0Not reportedNot reportedNot reported
Dose Escalation Cohort 5: RO7297089192025.4Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        26.3
        value
        12.7
      2. group Id
        OG001
        spread
        31.3
        value
        78.7
      3. group Id
        OG002
        spread
        73.6
        value
        280
      4. comment
        Only 1 participant analyzed
        group Id
        OG003
        spread
        NA
        value
        1347
      5. group Id
        OG004
        spread
        28.0
        value
        1046
      6. group Id
        OG005
        spread
        25.4
        value
        1920
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      4
    3. group Id
      OG002
      value
      3
    4. group Id
      OG003
      value
      1
    5. group Id
      OG004
      value
      4
    6. group Id
      OG005
      value
      3
    units
    Participants
dispersion Type
Standard Deviation
groups
  1. description
    Participants in Arm A received 60 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit
    id
    OG000
    title
    Dose Escalation Cohort 1: RO7297089
  2. description
    Participants in Arm A received 180 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit
    id
    OG001
    title
    Dose Escalation Cohort 2: RO7297089
  3. description
    Participants in Arm A received 360 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit
    id
    OG002
    title
    Dose Escalation Cohort 3: RO7297089
  4. description
    Participants in Arm A received 1080 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit
    id
    OG003
    title
    Dose Escalation Cohort 4: RO7297089
  5. description
    Participants in Arm B received the 1080 mg dose of RO7297089 as a split dose divided over two days (Days 1 and 2). The full target dose wasadministered at subsequent study drug administration visits.
    id
    OG004
    title
    Dose Escalation Backfill Cohort 4: RO7297089
  6. description
    Participants in Arm B received the 1850 mg dose of RO7297089 as a split dose divided over two days (Days 1 and 2). The full target dose was administered at subsequent study drug administration visits.
    id
    OG005
    title
    Dose Escalation Cohort 5: RO7297089
param Type
GEOMETRIC_MEAN
population Description
Only those participants who received full dose were included in the results summary
reporting Status
POSTED
time Frame
Cycle 1 Day 1
title
Area Under the Curve (AUC) of RO7297089
type
SECONDARY
unit Of Measure
ug/mL*day

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice